BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001
BIOCORRX INC NEW (BICX)
NASDAQ:AMEX Investor Relations:
ir.biocorrx.com
Company Research
Source: GlobeNewswire
ANAHEIM, CA, Oct. 09, 2018 (GLOBE NEWSWIRE) -- VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced the execution of a letter of intent (LOI) with VDM Biochemicals, Inc. (VDM), subject to execution of a definitive agreement, whereby the companies would partner to further develop and commercialize VDM’s new opioid antagonist molecule, VDM-001, as described in U.S. Patent # 9,650,338B1 – 2017: “Opioid antagonist compounds and methods of making and using.” Under the agreement, BioCorRx has the right of first refusal to acquire up to a 49% ownership stake in VDM-001, which was invented by Dr. Vardan Martirosyan. Both parties have agreed to use best efforts to enter into a definitive agreement within 6 months from the date of the
Show less
Read more
Impact Snapshot
Event Time:
BICX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BICX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BICX alerts
High impacting BIOCORRX INC NEW news events
Weekly update
A roundup of the hottest topics
BICX
News
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia [Yahoo! Finance]Yahoo! Finance
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and SchizophreniaGlobeNewswire
- BioCorRx Reports Business Update for 2023 [Yahoo! Finance]Yahoo! Finance
- BioCorRx Reports Business Update for 2023GlobeNewswire
- BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD [Yahoo! Finance]Yahoo! Finance
BICX
Sec Filings
- 5/1/24 - Form 4
- 4/5/24 - Form 4
- 4/3/24 - Form 8-K
- BICX's page on the SEC website